Business Wire

Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2022 Virtual Annual Meeting of Shareholders held on May 16, 2022 (the Meeting), all nominees listed in the management proxy circular dated April 8, 2022 were elected as directors of the Company.


The detailed results of the votes by proxy and virtual votes received at the Meeting are as follows:

DIRECTOR NOMINEES


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


WITHHELD


FOR


WITHHELD


Daniel Chicoine


3,229,640


334,343


90.62


9.38


Anthony Dobranowski


3,293,159


270,824


92.40


7.60


Robert Harris


3,319,014


244,969


93.13


6.87


John London


3,112,855


451,128


87.34


12.66


Mary Ritchie


3,364,247


199,736


94.40


5.60


Dale MacCandlish Weil


3,363,540


200,443


94.38


5.62

In addition, the Company reports that the appointment of Ernst & Young LLP as the Company’s auditors for the ensuing fiscal year was passed by a majority of the votes represented at the Meeting. The Company’s full report of voting results on matters presented at the Meeting can be found at www.sedar.com.

About Miravo Healthcare

Miravo is a Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.


Contacts

Investor Relations
Stefan Eftychiou
905 326 1888 ext 60
stefan@bristolir.com

READ ON BUSINESS WIRE

Back